)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shanghai Allist Pharmaceuticals
Shanghai Allist Pharmaceuticals (688578) investor relations material
Shanghai Allist Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
Q3 2026 revenue was RMB 18.16亿元, up 33.58% YoY; net profit attributable to shareholders was RMB 7.92亿元, up 40.38% YoY.
9M revenue reached RMB 51.35亿元, up 37.57% YoY, and attributable net profit was RMB 23.33亿元, up 44.41% YoY, driven by stronger product sales.
Financial highlights
9M total profit was RMB 2,725,487,528.19, up 44.30% YoY; Q3 total profit was RMB 924,607,762.39, up 41.54%.
Adjusted for non-recurring items, attributable net profit was RMB 767,728,492.29 in Q3, up 40.50%, and RMB 2,134,383,895.53 for 9M, up 47.04%.
9M operating cash flow was RMB 2,426,236,719, up 40.22% YoY; basic and diluted EPS were RMB 5.19, up 44.41%.
Outlook and guidance
Commercialization plans call for strengthening platform capabilities and using specialized, differentiated academic promotion to expand the reach of marketed products.
If approved, furmonertinib’s accepted adjuvant-treatment application would extend its use from advanced disease into post-surgical treatment of early-stage NSCLC.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shanghai Allist Pharmaceuticals
- Revenue and net profit soared on strong oncology sales and pipeline progress.688578
Q2 2026 - H1 2024 revenue and profit surged over 100% YoY, led by core product sales and cost control.688578Q2 2024
- Revenue and profit surged on Furmonertinib sales; R&D and pipeline expansion accelerated.688578Q4 2024
- Q3 revenue and net profit more than doubled year-over-year, fueled by strong oncology sales.688578Q3 2024
- Revenue up 47.86% and net profit up 34.13% year-over-year, led by oncology drug growth.688578Q1 2025
- RMB 0.40 per share cash dividend to be paid September 10, 2025, totaling RMB 180 million.688578Q2 2025
- Net profit surged 53.1% to ¥2.19 billion on 45.8% revenue growth, with robust oncology sales.688578Q4 2025
- Revenue and net profit soared on core drug sales, with new approvals set to drive future growth.688578Q3 2025
- Q1 revenue and profit surged on robust oncology drug sales and expanded insurance coverage.688578Q1 2026
Next Shanghai Allist Pharmaceuticals earnings date
Q4 202626 Apr, 2027
Shanghai Allist Pharmaceuticals
Next Shanghai Allist Pharmaceuticals earnings date
Q4 202626 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)